ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1814

Epidemiology and Microbiology of Pneumonia in Systemic Lupus Erythematosus (SLE)

Gabriela García-Guevara1, Ricardo Ríos-Corzo2, Hilda Fragoso-Loyo3, Juan Jakez-Ocampo4, John Hernandez-Flores2, Mariana Lopez-Lopez5, Eduardo Carrillo-Maravilla6, Jose Sifuentes-Osornio2 and Yemil Atisha-Fregoso7, 1Internal Medicine, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico, 2Internal Medicine, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 3Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 4Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, Mexico, 5Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 6Medicina Interna, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, 7Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Pneumonia, remains as a main cause of mortality in patients with SLE. There are not specific guidelines for the empiric treatment in these patients. The aim of this study was to establish the epidemiological characteristics, the microbiological isolations and the rate of complications of patients with SLE and pneumonia.

Methods: We retrospectively reviewed medical records of patients with SLE (ACR criteria) and Pneumonia who attended the emergency room in a single tertiary care center, (January 2010 – March 2015). We collected laboratory and clinical data: demographics, treatment and disease activity (SLEDAI-2K). We collected isolation data from the microbiology department and from the medical record to ascertain that the isolation was considered responsible of pneumonia. Patients were followed for 30 days after discharge. A negative outcome was defined as need of mechanical ventilation (MV), septic shock or death during follow-up. Statistics. Descriptive statistics were used.

Results: We included 163 patients (121 women, 74%), who presented 194 episodes of pneumonia. At evaluation the mean ± SD age was 34.6 ± 12.4 years, time since diagnosis of SLE 7.1 ± 8.2 years and SLEDAI 2K was 8 ± 5.6. Duration of hospitalization was 10.7 ± 7.2 days. In 154 of the episodes patients were taken prednisone (mean dose 18 mg). In fifty eight of the episodes (29.8%) was possible to obtain a positive microbiology report. The isolated microorganisms are depicted in table 1. Fifty seven (29%) patients presented a negative outcome: 13 (7%) septic shock, 50 (26%) needed MV and 12 (6%) patients died.

Table 1. Isolated microorganisms in 58 pneumonia episodes in SLE patients
n %
Streptococccus pneumoniae 4 6.8
Pseudomonas aeruginosa 8 13.7
Aspergillus 7 12
Klebsiella pneumoniae 5 8.6
Methicillin-sensitive Staphylococcus aureus 5 8.6
Methicillin-resistant Staphylococcus aureus 4 6.8
E. coli 4 6.8
Strepnotrophomonas 3 5.1
Enterococcus 2 3.4
Moraxella 2 3.4
S. epidermidis 2 3.4
H.parainfluenza 2 3.4
Enterobacter cloacae 2 3.4
Acinetobacter 2 3.4
Mycobacterium tuberculosis 1 1.7
Streptococcus agalactiae 1 1.7
Candida albicans 1 1.7
H. influenza 1 1.7
P. jirovecci 1 1.7
Serratia 1 1.7
TOTAL 58 100

Conclusion: In this study, a high proportion of patients with SLE and pneumonia presented a negative outcome. With an acceptable percentage of episodes with microbiological isolation, we identified a very high incidence of atypical microorganisms, this must be taken into account for empirical antibiotic selection in these patients.


Disclosure: G. García-Guevara, None; R. Ríos-Corzo, None; H. Fragoso-Loyo, None; J. Jakez-Ocampo, None; J. Hernandez-Flores, None; M. Lopez-Lopez, None; E. Carrillo-Maravilla, None; J. Sifuentes-Osornio, None; Y. Atisha-Fregoso, None.

To cite this abstract in AMA style:

García-Guevara G, Ríos-Corzo R, Fragoso-Loyo H, Jakez-Ocampo J, Hernandez-Flores J, Lopez-Lopez M, Carrillo-Maravilla E, Sifuentes-Osornio J, Atisha-Fregoso Y. Epidemiology and Microbiology of Pneumonia in Systemic Lupus Erythematosus (SLE) [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/epidemiology-and-microbiology-of-pneumonia-in-systemic-lupus-erythematosus-sle/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/epidemiology-and-microbiology-of-pneumonia-in-systemic-lupus-erythematosus-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology